Fig. 3: CM of IGR-B2T cells promotes CD103 expression in activated human CD8⁺ T cells.

a Representative flow cytometry plots (bi-exponential scale) of the expression of CD103 in CD8⁺ T cells from HD PBMC stimulated for three days with plastic-coated anti-CD3 mAb in the presence of CM from IGR-B2T or IGR-B2T-KO cells. Right, percentages of CD103⁺ cells among CD8⁺ T cells of non-stimulated and stimulated PBMC (n = 3). Recombinant (r)TGF-β at 1 ng/ml (+) or 5 ng/ml (++) was used as a positive control (*p = 0.011, ****p < 0.0001). b Percentages of CD103⁺ cells among CD8⁺ T lymphocytes from HD PBMC unstimulated or stimulated for three days with anti-CD3 alone, rTGF-β alone, CM alone, and a combination of anti-CD3 plus CM from IGR-B2T or IGR-B2T-KO cells (n = 6). Right, rescue experiments. Percentages of CD103⁺ lymphocytes among CD8⁺ T cells stimulated with a combination of anti-CD3 plus CM from IGR-B2T-KO cells, CM from IGR-B2T-KO plus low dose (1 ng/ml) of rTGF-β, and anti-CD3 plus rTGF-β, included as a control (n = 3, *p = 0.048, ****p < 0.0001). c Inhibition of CD103 induction with anti-TGF-β blocking mAb. Percentages of CD103⁺ lymphocytes among CD8⁺ T cells stimulated with CM from IGR-B2T plus anti-CD3 in the absence and presence of anti-TGF-β mAb (n = 6, *p = 0.022). A combination of anti-CD3 and rTGF-β alone and in presence of neutralizing anti-TGF-β was included as a control. Each symbol represents an individual cell type. Horizontal lines correspond to mean ± SEM. Data were calculated with one-way ANOVA with Tukey’s correction (a, b) and paired Student t-test (c). Source data are provided as a Source Data file.